melanoma, renal cell carcinoma, autoinflammatory diseases
Conditions
Interventions
None listed
Sponsors
Erasmus MC
Eligibility
Inclusion criteria
Inclusion criteria: 1. Population with immunotherapy-related organ specific toxicity ? Planned treatment with (intravenous) checkpoint inhibitors for any type of cancer according to standard of care. ? Age =18 years ? Able to understand the written information and able to give informed consent 2. Population with immune-mediated organ specific disease ? Patients with immune-mediated organ specific disease including, but not limited to, immune-mediated colitis such as ulcerative colitis, Crohn’s disease or auto-immune hepatitis ? Age =18 years ? Able to understand the written information and able to give informed consent
Exclusion criteria
Exclusion criteria: 4.2 Exclusion criteria ? Unable to draw blood for study purposes
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary study endpoint is the detection of organspecific methylation patterns in cell-free DNA during an irAE. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints are the levels of other biomarkers of inflammation during immunotherapy-mediated toxicity and the comparison organ-specific methylation profiles in blood with other biomarkers of inflammation. | — |
Contacts
Public ContactManouk Bos
Erasmus MC
Outcome results
None listed